Durable antibody response reported for the ABNCoV2 COVID-19 vaccine six months after vaccination in the Phase II clinical trial
Hørsholm, Denmark, October 17, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that follow-up results from Bavarian Nordic’s Phase II clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine show that antibody titers remained high at levels associated with greater than 90% efficacy six months after vaccination for both the Wuhan and the Omicron variant.Previously reported results from the trial showed that vaccination with 100ug ABNCoV2 in 103 seropositive subjects was able to demonstrate a